Cascadian Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 06 2016 - 8:00AM
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that Scott Myers,
President and CEO, and Luke Walker, M.D., Vice President of
Clinical Development, will present a corporate overview at the
Rodman & Renshaw 18th Annual Global Investment Conference. The
presentation will take place at 5:30pm EDT on Tuesday,
September 13, 2016 in New York City.
A live and archived webcast of the presentation will be
accessible on the "Events & Presentations" page of the "News
& Events" section of Cascadian Therapeutics' website at
www.cascadianrx.com.
About Cascadian Therapeutics Cascadian
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative product candidates for the
treatment of cancer. Our lead product candidate, tucatinib, also
known as ONT-380, is an orally active and selective small molecule
HER2 inhibitor, which has been studied in approximately 200
patients to date. Preliminary results from two ongoing Phase 1b
studies of tucatinib in combination showed promising systemic
activity, a favorable safety profile and encouraging activity
against brain metastases. Cascadian Therapeutics is also conducting
a randomized, double-blind, placebo-controlled Phase 2 study called
HER2CLIMB. The study is evaluating tucatinib versus placebo in
combination with capecitabine and trastuzumab in late stage HER2+
breast cancer patients, with and without brain metastases, who have
previously been treated with a taxane, trastuzumab, pertuzumab and
T-DM1. This study is expected to enroll 180 patients with and
without brain metastases across approximately 100 clinical sites in
the U.S., Canada, and Western Europe. The Company is also
developing a cell cycle inhibitor, Chk1, and plans to move the
program forward through IND-enabling studies in 2017. For more
information, visit www.cascadianrx.com.
Investor Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@cascadianrx.com
Tricia Truehart
The Trout Group
646-378-2953
ttruehart@troutgroup.com
Media Contact:
Amy Bonanno
BMC Communications
646-513-3117
abonanno@bmccommunications.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2023 to Sep 2024